Skip to main content
Erschienen in: Clinical Oral Investigations 9/2014

01.12.2014 | Original Article

Analysis of reasons for osteonecrosis of the jaws

verfasst von: Christian Walter, Keyvan Sagheb, Jennifer Bitzer, Roman Rahimi-Nedjat, Katherine Joyce Taylor

Erschienen in: Clinical Oral Investigations | Ausgabe 9/2014

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Osteonecroses of the jaws are caused by several reasons. Bisphosphonate-associated osteonecrosis of the jaws (BP-ONJ) is known since 2003 with an increasing incidence in the first years. Along with more knowledge about the pathophysiology, preventive strategies were implemented trying to reduce the incidence. The aim of this retrospective study was to analyze the frequency and overall proportion of BP-ONJ within the field of osteonecrosis. The data was compared to a similar study performed in 2005.

Methods

All patients with osteonecrosis or osteomyelitis treated in the period from April 2005 to July 2012 in the Oral and Maxillofacial Surgery at the University of Mainz, Germany, were analyzed.

Results

The reasons for osteonecrosis were bisphosphonates in 45 %, odontogenic or surgically induced osteonecrosis in 32 %, osteoradionecrosis in 17 %, traumas in 1 %, and in 4 % the reason remained unclear. The BP-ONJ became the most important factor for osteonecrosis. Its fraction in the years 2000–2005 was 10 % only.

Conclusions

Although preventive strategies are implemented, the number of new cases got bigger. The implemented prevention strategies did not manage to reduce the overall number of new cases. Furthermore, the launch of other medications with a similar side effect on the jawbone as the BP-ONJ for bisphosphonates might influence the overall distribution of osteonecroses.
Literatur
1.
Zurück zum Zitat Marx RE (2003) Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of jaws: a growing epidemic. J Oral Maxillofac Surg 61(9):1115–1117PubMedCrossRef Marx RE (2003) Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of jaws: a growing epidemic. J Oral Maxillofac Surg 61(9):1115–1117PubMedCrossRef
2.
Zurück zum Zitat Tarassoff P, Csermak K (2003) Avascular necrosis of the jaws: risk factors in metastatic cancer patients. J Oral Maxillofac Surg 61(10):1238–1239PubMedCrossRef Tarassoff P, Csermak K (2003) Avascular necrosis of the jaws: risk factors in metastatic cancer patients. J Oral Maxillofac Surg 61(10):1238–1239PubMedCrossRef
3.
Zurück zum Zitat Walter C, Grotz KA, Kunkel M, Al-Nawas B (2007) Prevalence of bisphosphonate associated osteonecrosis of the jaw within the field of osteonecrosis. Support Care Cancer 15(2):197–202PubMedCrossRef Walter C, Grotz KA, Kunkel M, Al-Nawas B (2007) Prevalence of bisphosphonate associated osteonecrosis of the jaw within the field of osteonecrosis. Support Care Cancer 15(2):197–202PubMedCrossRef
4.
Zurück zum Zitat Walter C, Al-Nawas B, Frickhofen N, Gamm H, Beck J, Reinsch L, Blum C, Grotz KA, Wagner W (2011) Prevalence of bisphosphonate associated osteonecrosis of the jaws in multiple myeloma patients. Head Face Med 6:11CrossRef Walter C, Al-Nawas B, Frickhofen N, Gamm H, Beck J, Reinsch L, Blum C, Grotz KA, Wagner W (2011) Prevalence of bisphosphonate associated osteonecrosis of the jaws in multiple myeloma patients. Head Face Med 6:11CrossRef
5.
Zurück zum Zitat Walter C, Al-Nawas B, Grotz KA, Thomas C, Thuroff JW, Zinser V, Gamm H, Beck J, Wagner W (2008) Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate. Eur Urol 54(5):1066–1072PubMedCrossRef Walter C, Al-Nawas B, Grotz KA, Thomas C, Thuroff JW, Zinser V, Gamm H, Beck J, Wagner W (2008) Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate. Eur Urol 54(5):1066–1072PubMedCrossRef
6.
Zurück zum Zitat Walter C, Al-Nawas B, du Bois A, Buch L, Harter P, Grotz KA (2009) Incidence of bisphosphonate-associated osteonecrosis of the jaws in breast cancer patients. Cancer 115(8):1631–1637PubMedCrossRef Walter C, Al-Nawas B, du Bois A, Buch L, Harter P, Grotz KA (2009) Incidence of bisphosphonate-associated osteonecrosis of the jaws in breast cancer patients. Cancer 115(8):1631–1637PubMedCrossRef
7.
Zurück zum Zitat Walter C, Klein MO, Pabst A, Al-Nawas B, Duschner H, Ziebart T (2010) Influence of bisphosphonates on endothelial cells, fibroblasts, and osteogenic cells. Clin Oral Investig 14(1):35–41PubMedCrossRef Walter C, Klein MO, Pabst A, Al-Nawas B, Duschner H, Ziebart T (2010) Influence of bisphosphonates on endothelial cells, fibroblasts, and osteogenic cells. Clin Oral Investig 14(1):35–41PubMedCrossRef
8.
Zurück zum Zitat Ziebart T, Pabst A, Klein MO, Kammerer P, Gauss L, Brullmann D, Al-Nawas B, Walter C (2011) Bisphosphonates: restrictions for vasculogenesis and angiogenesis: inhibition of cell function of endothelial progenitor cells and mature endothelial cells in vitro. Clin Oral Investig 15(1):105–111. doi:10.1007/s00784-009-0365-2 PubMedCrossRef Ziebart T, Pabst A, Klein MO, Kammerer P, Gauss L, Brullmann D, Al-Nawas B, Walter C (2011) Bisphosphonates: restrictions for vasculogenesis and angiogenesis: inhibition of cell function of endothelial progenitor cells and mature endothelial cells in vitro. Clin Oral Investig 15(1):105–111. doi:10.​1007/​s00784-009-0365-2 PubMedCrossRef
9.
Zurück zum Zitat Pabst AM, Ziebart T, Koch FP, Taylor KY, Al-Nawas B, Walter C (2012) The influence of bisphosphonates on viability, migration, and apoptosis of human oral keratinocytes—in vitro study. Clin Oral Investig 16(1):87–93. doi:10.1007/s00784-010-0507-6 PubMedCrossRef Pabst AM, Ziebart T, Koch FP, Taylor KY, Al-Nawas B, Walter C (2012) The influence of bisphosphonates on viability, migration, and apoptosis of human oral keratinocytes—in vitro study. Clin Oral Investig 16(1):87–93. doi:10.​1007/​s00784-010-0507-6 PubMedCrossRef
10.
Zurück zum Zitat Allen MR, Burr DB (2009) The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: so many hypotheses, so few data. J Oral Maxillofac Surg 67(5 Suppl):61–70PubMedCrossRef Allen MR, Burr DB (2009) The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: so many hypotheses, so few data. J Oral Maxillofac Surg 67(5 Suppl):61–70PubMedCrossRef
11.
Zurück zum Zitat Walter C, Laux C, Sagheb K (2013) Radiologic bone loss in patients with bisphosphonate-associated osteonecrosis of the jaws: a case-control study. Clin Oral Investig. doi:10.1007/s00784-013-0974-7 Walter C, Laux C, Sagheb K (2013) Radiologic bone loss in patients with bisphosphonate-associated osteonecrosis of the jaws: a case-control study. Clin Oral Investig. doi:10.​1007/​s00784-013-0974-7
13.
Zurück zum Zitat Blus C, Szmukler-Moncler S, Giannelli G, Denotti G, Orru G (2013) Use of ultrasonic bone surgery (Piezosurgery) to surgically treat bisphosphonate-related osteonecrosis of the jaws (BRONJ). A case series report with at least 1 year of follow-up. Open Dent J 7:94–101. doi:10.2174/1874210601307010094 PubMedCentralPubMedCrossRef Blus C, Szmukler-Moncler S, Giannelli G, Denotti G, Orru G (2013) Use of ultrasonic bone surgery (Piezosurgery) to surgically treat bisphosphonate-related osteonecrosis of the jaws (BRONJ). A case series report with at least 1 year of follow-up. Open Dent J 7:94–101. doi:10.​2174/​1874210601307010​094 PubMedCentralPubMedCrossRef
14.
Zurück zum Zitat Assaf AT, Zrnc TA, Riecke B, Wikner J, Zustin J, Friedrich RE, Heiland M, Smeets R, Grobe A (2013) Intraoperative efficiency of fluorescence imaging by Visually Enhanced Lesion Scope (VELscope) in patients with bisphosphonate related osteonecrosis of the jaw (BRONJ). J Craniomaxillofac Surg. doi:10.1016/j.jcms.2013.07.014 Assaf AT, Zrnc TA, Riecke B, Wikner J, Zustin J, Friedrich RE, Heiland M, Smeets R, Grobe A (2013) Intraoperative efficiency of fluorescence imaging by Visually Enhanced Lesion Scope (VELscope) in patients with bisphosphonate related osteonecrosis of the jaw (BRONJ). J Craniomaxillofac Surg. doi:10.​1016/​j.​jcms.​2013.​07.​014
15.
Zurück zum Zitat Grötz KA, Kreusch T (2006) Zahnärztliche Betreuung von Patienten unter/nach Bisphosphonat-Medikation. DZZ 60:10 Grötz KA, Kreusch T (2006) Zahnärztliche Betreuung von Patienten unter/nach Bisphosphonat-Medikation. DZZ 60:10
16.
Zurück zum Zitat Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B (2009) American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws—2009 update. J Oral Maxillofac Surg 67(5 Suppl):2–12PubMed Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B (2009) American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws—2009 update. J Oral Maxillofac Surg 67(5 Suppl):2–12PubMed
17.
Zurück zum Zitat Grötz KA, Piesold JU, Al-Nawas B (2012) AWMF Leitlinie Bisphosphonat-assoziierte Kiefernekrose (BP-ONJ) und andere Medikamenten-assoziierte Kiefernekrosen. AWMF Grötz KA, Piesold JU, Al-Nawas B (2012) AWMF Leitlinie Bisphosphonat-assoziierte Kiefernekrose (BP-ONJ) und andere Medikamenten-assoziierte Kiefernekrosen. AWMF
18.
Zurück zum Zitat Montefusco V, Gay F, Spina F, Miceli R, Maniezzo M, Teresa Ambrosini M, Farina L, Piva S, Palumbo A, Boccadoro M, Corradini P (2008) Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates. Leuk Lymphoma 49(11):2156–2162PubMedCrossRef Montefusco V, Gay F, Spina F, Miceli R, Maniezzo M, Teresa Ambrosini M, Farina L, Piva S, Palumbo A, Boccadoro M, Corradini P (2008) Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates. Leuk Lymphoma 49(11):2156–2162PubMedCrossRef
19.
Zurück zum Zitat Bonacina R, Mariani U, Villa F, Villa A (2011) Preventive strategies and clinical implications for bisphosphonate-related osteonecrosis of the jaw: a review of 282 patients. J Can Dent Assoc 77:b147PubMed Bonacina R, Mariani U, Villa F, Villa A (2011) Preventive strategies and clinical implications for bisphosphonate-related osteonecrosis of the jaw: a review of 282 patients. J Can Dent Assoc 77:b147PubMed
22.
Zurück zum Zitat Advisory Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws AAoOaMS (2007) American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 65(3):369–376CrossRef Advisory Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws AAoOaMS (2007) American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 65(3):369–376CrossRef
23.
Zurück zum Zitat Schwabe U, Paffrath D (2007) Arzneimittelverordnungs-Report 2006: Aktuelle Daten, Kosten, Trends und Kommentare. Springer, HeidelbergCrossRef Schwabe U, Paffrath D (2007) Arzneimittelverordnungs-Report 2006: Aktuelle Daten, Kosten, Trends und Kommentare. Springer, HeidelbergCrossRef
24.
Zurück zum Zitat Schwabe U, Paffrath D (2012) Arzneiverordnungs-Report 2012: Aktuelle Daten, Kosten, Trends und Kommentare. Springer, HeidelbergCrossRef Schwabe U, Paffrath D (2012) Arzneiverordnungs-Report 2012: Aktuelle Daten, Kosten, Trends und Kommentare. Springer, HeidelbergCrossRef
25.
Zurück zum Zitat Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J, Scagliotti GV, Sleeboom H, Spencer A, Vadhan-Raj S, von Moos R, Willenbacher W, Woll PJ, Wang J, Jiang Q, Jun S, Dansey R, Yeh H (2011) Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 29(9):1125–1132. doi:10.1200/JCO.2010.31.3304 PubMedCrossRef Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J, Scagliotti GV, Sleeboom H, Spencer A, Vadhan-Raj S, von Moos R, Willenbacher W, Woll PJ, Wang J, Jiang Q, Jun S, Dansey R, Yeh H (2011) Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 29(9):1125–1132. doi:10.​1200/​JCO.​2010.​31.​3304 PubMedCrossRef
26.
Zurück zum Zitat Guarneri V, Miles D, Robert N, Dieras V, Glaspy J, Smith I, Thomssen C, Biganzoli L, Taran T, Conte P (2010) Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer. Breast Cancer Res Treat 122(1):181–188PubMedCrossRef Guarneri V, Miles D, Robert N, Dieras V, Glaspy J, Smith I, Thomssen C, Biganzoli L, Taran T, Conte P (2010) Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer. Breast Cancer Res Treat 122(1):181–188PubMedCrossRef
Metadaten
Titel
Analysis of reasons for osteonecrosis of the jaws
verfasst von
Christian Walter
Keyvan Sagheb
Jennifer Bitzer
Roman Rahimi-Nedjat
Katherine Joyce Taylor
Publikationsdatum
01.12.2014
Verlag
Springer Berlin Heidelberg
Erschienen in
Clinical Oral Investigations / Ausgabe 9/2014
Print ISSN: 1432-6981
Elektronische ISSN: 1436-3771
DOI
https://doi.org/10.1007/s00784-014-1205-6

Weitere Artikel der Ausgabe 9/2014

Clinical Oral Investigations 9/2014 Zur Ausgabe

Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Zahnmedizin und bleiben Sie gut informiert – ganz bequem per eMail.